RxDoctor Payments Data

Andrea Raymond, MD

Neurology · Austin, TXNPI 1538181920

Payments from drug & device makers

$237,632in general payments, 2019–2025

Across 472 payments — averaging $503.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$159K
  • AbbVie$58K
  • Novo Nordisk AS$15K
  • Lilly USA, LLC$656
  • Teva Pharmaceuticals USA, Inc.$562
  • Amgen$549
  • plus $4K from 50 others
$10,740in research payments, 2019–2025

Across 2 payments — averaging $5369.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$11K

What the payments were for

  • Consulting fees$2,97512%
  • Speaking & faculty fees$13,32354%
  • Travel & lodging$1,1505%
  • Food & beverage$7,00628%
  • Education$2031%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$237,632 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$168,298
Medicare patients
330
Services billed
9,855

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlatopaGlatiramer Acetate13$55,438
RytaryCarbidopa/Levodopa36$39,848
Nurtec OdtRimegepant Sulfate19$35,551
Lamictal XrLamotrigine11$26,297
Emgality PenGalcanezumab-Gnlm25$22,379
UbrelvyUbrogepant12$16,354
Aimovig AutoinjectorErenumab-Aooe16$14,314
Lamotrigine ErLamotrigine19$6,285
Carbidopa-LevodopaCarbidopa/Levodopa196$5,645
Rasagiline Mesylate16$5,441
Donepezil Hcl398$4,164
Memantine Hcl219$3,867
Levetiracetam99$3,666
Rivastigmine22$2,995
Pregabalin135$2,739

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$298$42,54788 claims
PfizerNurtec Odt$121$35,55119 claims
AbbVieUbrelvy$57,904$16,35412 claims
Almatica Pharma LLCSertraline Hcl$14$52315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.

Other neurology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →